Yes, you are correct. And as Pyrr pointed out, if CLDX does obtain early approval and market entry, it constitute yet another trailblazer widening the path for DCVax. I see this as a win-win. Ultimately, CLDX EGFRvIII tech may be absorbed by licensing, merger or sale -- because it is limited; but for now, it will benefit from early entry.
News 
Market Data 
Discover 
